TheEdgeResearch
Home / Stocks / GZPHF

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (GZPHF)

OTC Healthcare Drug Manufacturers - Specialty & Generic
$2.34 ▲ +0.00%
Market Cap
$6.20B
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Beta
0.18
52-Wk Range
2.14-2.88
CEO
Hong Li
Country
CN
Currency
USD

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Guangzhou, GD, CN. The stock last traded at $2.34, up 0.00% on the session, giving a market capitalisation of $6.20B. On trailing twelve-month figures it carries a trailing P/E of 11.81, a net margin of 3.8%. Its beta of 0.18 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
11.81
Price / Sales
0.45
Price / Book
0.88
EV / EBITDA
10.34
Gross margin
16.0%
Operating margin
4.1%
Net margin
3.8%
Return on equity
Debt / equity
0.59
Current ratio
1.60
Dividend yield
4.0%
Payout ratio
69.5%
Company profile
Exchange
Other OTC
Employees
27,057
IPO date
2010-01-05
Headquarters
Guangzhou, GD, CN
About Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (GZPHF), operating with its various subsidiaries, is a diversified pharmaceutical conglomerate primarily engaged in the research, development, manufacturing, and global distribution of a broad spectrum of medical products. This includes traditional Chinese patented medicines, Western pharmaceuticals, chemical raw materials, natural and biological medicines, as well as chemical raw material intermediates. The company's reach extends throughout the People's Republic of China and into international markets. Its operations are strategically divided into four primary segments: Great Southern TCM, Great Commerce, Great Health, and an 'Others' category. Beyond its core pharmaceutical activities, GZPHF also handles the wholesale, retail, import, and export of both Western and Chinese medicines, alongside medical apparatus and instruments. Furthermore, the company is involved in the innovation, production, and sale of a diverse range of consumer goods such as beverages, food items, health supplements, pre-packaged foods, dairy products, and various pharmaceutical forms including tablets, capsules, lozenges, and injections, even extending to traditional tortoise herb jelly. Additionally, the company strategically invests in the broader health industry, encompassing areas like medical services, health management, wellness and preservation, and elderly care. It also provides commercial and advertising services. As of December 31, 2021, GZPHF maintained a significant retail presence with 154 chain pharmacy outlets. These comprised 22 Cai Zhi Lin pharmacy locations, 36 Jian Min pharmacy outlets, 51 GPC Prescription Pharmacy stores, and 23 Hainan Guangyao Chenfei Pharmaceutical Chain Co., Ltd. outlets. Complementing these, the company also operated 22 general retail stores. The enterprise, headquartered in Guangzhou, China, was established in 1997. It was formerly known as Guangzhou Pharmaceutical Company Limited before officially adopting its current name, Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, in August 2013.

Comparable companies

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited is most often compared with the following Healthcare names:

DNPUFHKMPFHKMPYHLBBFHLUBFLVZPFOPHLFOPHLYSHPMYSMDPY
More research on GZPHF
GZPHF technical analysis GZPHF TheEdge Score Compare against peers
Open full interactive analysis & DCF →